Evaluation of Safety and Efficacy of Three Flavors of Supportan® Drink in Cancer Patients in Taiwan
Launched by FRESENIUS KABI TAIWAN LTD. · Mar 23, 2025
Trial Information
Current as of April 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients receiving chemotherapy and/or radiotherapy, or immunotherapy, or targeted therapy;
- • 2. Patient with diagnosed cancer of any type (e.g., head and neck cancer, lung cancer, digestive tract cancer, breast cancer);
- • 3. Patient with or at risk of malnutrition defined as meeting Malnutrition Universal Screening Tool (MUST) with score ≥2;
- • 4. Capable of using oral nutritional supplementation;
- • 5. Written informed consent from patient.
- Exclusion Criteria:
- • 1. Patient with documented diagnosis of liver, kidney or heart disease in the hospital's electronic medical record (EMR); severity of disease evaluated by Investigator as not being suitable to participate in this study;
- • 2. Current alcohol or substance abuse as assessed by Investigator;
- • 3. Patient had a stroke in the past year and is after Investigator assessment judged as not yet clinically stable at the time of screening;
- • 4. Patients who are diagnosed with mental illness or depression assessed by the Investigator as too severe for being suitable to participate in this study;
- • 5. Pregnant or breastfeeding woman;
- • 6. Allergic to any ingredient of the investigational products;
- • 7. Patients receiving or having received standard (not disease specific) oral nutritional supplements (ONS), standard enteral formula/tube feeding or standard parenteral cancerspecific nutrition supplements in the last 3 days;
- • 8. Patients receiving or having received ONS, enteral formula/tube feeding or parenteral nutrition with high fish oil or high EPA/DHA content (above 1 g/day) in the last 28 days;
- • 9. Current use of medication, food supplements or ONS containing more than 500 mg of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)/day or fish oil capsules/supplements containing more than 500 mg EPA and DHA/day at screening;
- • 10. Transfusion of blood products within 1 week before screening;
- • 11. Surgery scheduled during the trial;
- • 12. Participation in other clinical trials using investigational drugs within 14 days before the start of the trial or during the trial.
About Fresenius Kabi Taiwan Ltd.
Fresenius Kabi Taiwan Ltd. is a leading global healthcare company dedicated to the development and provision of innovative pharmaceutical products and medical devices. Specializing in parenteral nutrition, IV drugs, and infusion therapies, the company is committed to enhancing patient outcomes through high-quality, safe, and effective solutions. With a strong emphasis on research and development, Fresenius Kabi Taiwan actively engages in clinical trials to advance medical knowledge and optimize therapeutic options, ensuring that healthcare professionals and patients have access to cutting-edge treatments. The company operates under stringent regulatory standards, reinforcing its dedication to excellence in all aspects of healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Keelung, , Taiwan
Keelung, , Taiwan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported